The University of Chicago Header Logo

Connection

Steven Chmura to Radiosurgery

Back to Details
This is a "connection" page, showing publications Steven Chmura has written about Radiosurgery.
Steven Chmura
Connection Strength
11.915
Radiosurgery
  1. Flipping the Null: Lessons From Breast Cancer and Recalibrating Expectations in Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):840-842.
    View in: PubMed
    Score: 0.692
  2. From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):576-580.
    View in: PubMed
    Score: 0.688
  3. Oligometastatic Breast Cancer. Semin Radiat Oncol. 2022 07; 32(3):282-290.
    View in: PubMed
    Score: 0.675
  4. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.637
  5. Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. JAMA Oncol. 2021 Jun 01; 7(6):845-852.
    View in: PubMed
    Score: 0.626
  6. The role of immunotherapy in combination with oligometastasis-directed therapy: a narrative review. Ann Palliat Med. 2021 May; 10(5):6028-6044.
    View in: PubMed
    Score: 0.608
  7. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.598
  8. A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):189-195.
    View in: PubMed
    Score: 0.586
  9. The Evolution (and Future) of Stereotactic Body Radiotherapy in the Treatment of Oligometastatic Disease. Hematol Oncol Clin North Am. 2020 02; 34(1):307-320.
    View in: PubMed
    Score: 0.560
  10. Putting the "BR" in SBRT. Int J Radiat Oncol Biol Phys. 2018 09 01; 102(1):13-14.
    View in: PubMed
    Score: 0.515
  11. Reply to S.C. Formenti et al. J Clin Oncol. 2018 09 01; 36(25):2662-2663.
    View in: PubMed
    Score: 0.509
  12. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.498
  13. Oligometastasis-Directed Ablative Therapy: A Clinical Trial Question. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):448.
    View in: PubMed
    Score: 0.466
  14. Stereotactic body radiotherapy for oligometastatic breast cancer: a new standard of care, or a medical reversal in waiting? Expert Rev Anticancer Ther. 2016 Jun; 16(6):625-32.
    View in: PubMed
    Score: 0.441
  15. The role of surgery and ablative radiotherapy in oligometastatic breast cancer. Semin Oncol. 2014 Dec; 41(6):790-7.
    View in: PubMed
    Score: 0.395
  16. Treatment of brain metastases. Oncology. 2014; 87(6):321-9.
    View in: PubMed
    Score: 0.392
  17. Stereotactic radiotherapy for pulmonary metastases. Semin Thorac Cardiovasc Surg. 2013; 25(4):292-9.
    View in: PubMed
    Score: 0.375
  18. Evolving use of radiotherapy and radiosurgery in the treatment of pituitary adenomas. Expert Rev Anticancer Ther. 2006 Sep; 6 Suppl 9:S93-8.
    View in: PubMed
    Score: 0.225
  19. Combined Stereotactic Body Radiation Therapy and Immune Checkpoint Inhibition for Liver Metastases: Safety and Outcomes in a Pooled Analysis of 3 Phase 1 Trials. Int J Radiat Oncol Biol Phys. 2024 Apr 01; 118(5):1519-1530.
    View in: PubMed
    Score: 0.187
  20. Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases. J Clin Invest. 2023 05 15; 133(10).
    View in: PubMed
    Score: 0.179
  21. Intracranial and Extracranial Progression and Their Correlation With Overall Survival After Stereotactic Radiosurgery in a Multi-institutional Cohort With Brain Metastases. JAMA Netw Open. 2023 04 03; 6(4):e2310117.
    View in: PubMed
    Score: 0.178
  22. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It? Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):561-570.
    View in: PubMed
    Score: 0.172
  23. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.169
  24. Predictors of Pneumonitis in Combined Thoracic Stereotactic Body Radiation Therapy and Immunotherapy. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):645-654.
    View in: PubMed
    Score: 0.168
  25. Evaluation of Dose Distribution to Organs-at-Risk in a Prospective Phase 1 Trial of Pembrolizumab and Multisite Stereotactic Body Radiation Therapy (SBRT). Pract Radiat Oncol. 2022 Jan-Feb; 12(1):68-77.
    View in: PubMed
    Score: 0.160
  26. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.157
  27. Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS). J Appl Clin Med Phys. 2021 Mar; 22(3):196-206.
    View in: PubMed
    Score: 0.154
  28. Towards frameless maskless SRS through real-time 6DoF robotic motion compensation. Phys Med Biol. 2017 Nov 13; 62(23):9054-9066.
    View in: PubMed
    Score: 0.122
  29. Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. Am J Clin Oncol. 2017 Aug; 40(4):418-422.
    View in: PubMed
    Score: 0.120
  30. Benchmark Credentialing Results for NRG-BR001: The First National Cancer Institute-Sponsored Trial of Stereotactic Body Radiation Therapy for Multiple Metastases. Int J Radiat Oncol Biol Phys. 2017 01 01; 97(1):155-163.
    View in: PubMed
    Score: 0.113
  31. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.110
  32. Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e291-e298.
    View in: PubMed
    Score: 0.110
  33. The evolving role of radiotherapy in treatment of oligometastatic NSCLC. Expert Rev Anticancer Ther. 2015; 15(12):1459-71.
    View in: PubMed
    Score: 0.106
  34. The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
    View in: PubMed
    Score: 0.087
  35. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012 Jun 01; 118(11):2962-70.
    View in: PubMed
    Score: 0.080
  36. Classification for long-term survival in oligometastatic patients treated with ablative radiotherapy: A multi-institutional pooled analysis. PLoS One. 2018; 13(4):e0195149.
    View in: PubMed
    Score: 0.031
  37. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J Immunol. 2013 Jun 01; 190(11):5874-81.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.